Evidence map›Paper›PMID 38716804›Full record

Trial reportEpigenetics2024

Evaluating the utility of

Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, She Yu Lin, Fang-Shu Ou, Kelly Carter, Federico Innocenti, Leonard Saltz, William M Grady, Stacey A Cohen

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizabeth S NakasoneDivision of Oncology, University of Washington, Seattle, WA, USA.
Tyler J ZemlaAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
Ming YuTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
She Yu LinTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Fang-Shu OuAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
Kelly CarterTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Federico InnocentiDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Leonard SaltzDepartment of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William M GradyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Stacey A CohenDivision of Oncology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6207-9856

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCI NIH HHS P30 CA008748NCI NIH HHS UG1 CA233290
6 · The paper itself

Abstract

While epigenomic alterations are common in colorectal cancers (CRC), few epigenomic biomarkers that risk-stratify patients have been identified. We thus sought to determine the potential of

Indexed as

Biomarkers, TumorColonic NeoplasmsDNA MethylationPromoter Regions, GeneticAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisTranscription FactorsTrefoil Factor-3Biomarkers, TumorTFF3 protein, humanTranscription FactorsTrefoil Factor-3biomarkerCALGB 89803 (Alliance)DNA methylationepigenetic factorsstage III colon cancerZNF331

Identifiers

PMID38716804
PMCPMC11085945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.